Coronary heart disease is caused due to the narrowing or blockage of arteries leading to the heart. Credit: BruceBlaus.

The UK’s National Health Service (NHS) has adopted HeartFlow’s artificial intelligence (AI) technology across its network of hospitals to address coronary heart disease.

Under the Innovation and Technology Payment (ITP) programme, the HeartFlow FFRct Analysis is initially available in 13 NHS hospitals. The organisation plans to expand the technology to more than 35 hospitals over the coming months.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The technology is backed by deep learning and advanced algorithms. It is designed to help in diagnosing the cardiac disease by assessing blood flow to the heart.

“According to estimates by the National Institute for Health and Care Excellence (NICE), HeartFlow can save nearly £9.1m a year for the NHS.”

After a coronary computed tomography (CT) scan, the HeartFlow Analysis uses deep learning and data processing to create a detailed digital three-dimensional (3D) model of the patient’s arteries.

Subsequently, the technology applies advanced algorithms to solve numerous complex equations in order to assess the effect of any blockages on blood flow to the heart.

Currently, the majority of hospitals take several weeks to diagnose coronary heart disease and develop a treatment plan, and HeartFlow is expected to aid in reducing this timeline.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

HeartFlow president and CEO John Stevens said:  “We will be working hard to ensure HeartFlow can help improve the overall patient experience, by both helping physicians identify heart disease which may have otherwise been missed and delivering significant cost benefits to the NHS.”

The HeartFlow Analysis is said to deliver better diagnostic performance when compared to other commonly available approaches.

It also demonstrated the capability to detect coronary disease that is often missed by other tests. At the same time, the technology mitigated the requirement for unnecessary tests.

According to estimates by the National Institute for Health and Care Excellence (NICE), HeartFlow can save nearly £9.1m a year for the NHS.